Skip to content

Annotated patient-voice sources

Last curated: 2026-10-30. New sources accessed 2026-10-30; older entries retain their previous verification dates.

Peer-reviewed

  • Speight J, et al. Bringing an end to diabetes stigma and discrimination. Lancet Diabetes Endocrinol. 2024. PMID 38128969 — International consensus synthesising evidence and recommendations; strong agenda-setting source, not an intervention trial.
  • González-González JG, et al. Values, preferences and burden of treatment for GLP-1RA and SGLT2 initiation. BMJ Open. 2021;11:e049130. PMID 34244276 — Systematic review of treatment attributes and preferences; heterogeneous measures and settings.
  • Chopra S, et al. Effective primary care management of T2D for indigenous populations. PLoS One. 2022;17:e0276396. PMID 36355789 — Review focused on indigenous-care models; demonstrates context but should not be universalised across nations.
  • Seuring T, et al. Economic costs of T2D. Pharmacoeconomics. 2015;33:811-831. PMID 25787932 — Economic-burden synthesis; methods and country coverage highly heterogeneous.
  • Lean MEJ, et al. DiRECT one- and five-year reports. PMID 29221645; PMID 38423026 — Important for the hope/pressure tension around remission.

  • Joiner KL, et al. Promoting Stigma-Free Language in Type 2 Diabetes Care Among Primary Care Clinicians. JMIR Diabetes. 2026. PMID 42579884 — Randomised 21-clinician pilot; improved attitudes, but did not test sustained behaviour or patient outcomes.

  • Speight J, et al. EASD guideline on diabetes distress in adults. Diabetologia. 2026. PMID 42744915 — Includes people with lived experience in guideline development; assessment statements and T2D treatment recommendations have different evidence bases.

  • Schipper SBJ, et al. Interventions to reduce diabetes-related distress in adults. Diabetologia. 2026. PMID 42726276 — EASD-commissioned RCT synthesis; distress is the outcome, and most comparisons have low or very low certainty.

  • Zaghloul H, et al. Examining the facilitators and barriers to health behaviour change for type 2 diabetes remission in a young population with early diabetes: A qualitative study of participants in the DIADEM-I randomised controlled trial. Diabet Med. 2026. PMID 42944694 — Qualitative DIADEM-I substudy; catalogued from abstract, full text not retrieved; no new numerical or population-wide experience claim added.

Organizations and public resources

  • International Diabetes Federation — “Regions & Members.” https://idf.org/our-network/regions-and-members/ — Verifies global member structure; organisational description, not independent evaluation.
  • American Diabetes Association — “Advocacy.” https://diabetes.org/advocacy — Lists affordability, equity, discrimination and research priorities; US policy context.
  • Diabetes UK — “Diabetes stigma.” https://www.diabetes.org.uk/living-with-diabetes/emotional-wellbeing/stigma — Public education and campaign material; includes survey-derived claims but the page is not a peer-reviewed prevalence study.
  • Diabetes UK — “Our research helps shape world’s first diabetes distress guidance.” https://www.diabetes.org.uk/about-us/news-and-views/our-research-helps-shape-worlds-first-diabetes-distress-guidance — Posted 2026-09-24; patient-organisation account of the EASD guidance and D-Stress collaboration; accessed 2026-10-09.
  • Diabetes UK — “Helpline.” https://www.diabetes.org.uk/support-for-you/helpline — Verifies practical/emotional support service.
  • Diabetes Australia — “Position statements.” https://www.diabetesaustralia.com.au/position-statements/ — Hosts language guidance and national positions.

Public material added 2026-10-30

  • Diabetes UK — “Novo Nordisk to withdraw Levemir insulin – here’s what you need to know.” https://www.diabetes.org.uk/about-us/news-and-views/novo-nordisk-to-withdraw-levemir-what-you-need-to-know — Updated 2026-10-05; explains the approaching UK withdrawal, planned care transitions and device changes. Relevant to treatment continuity for insulin-treated T2D; an organisation’s support resource, not comparative treatment evidence. Accessed 2026-10-30.
  • Diabetes UK — “Parliamentary report highlights ‘indefensible failure’ of inadequate weight management services.” https://www.diabetes.org.uk/about-us/news-and-views/parliamentary-inquiry-report-calls-improved-weight-management-services — Posted 2026-10-22; public advocacy for equitable access to prevention, remission and weight-management services. Not a prevalence estimate or an independent effectiveness evaluation. Accessed 2026-10-30.

Coverage limitations

The source set is not a systematic sample of all patient experience. It overrepresents organizations with mature English websites, people willing to engage publicly, and health systems in high-income countries. No social-media posts or private forum material were collected. Future expansion should use translated public organisational sources and peer-reviewed qualitative studies from Africa, Latin America, South Asia and the Middle East.